Such desperation!!! BUT, the news agencies report it.
NEW YORK (Dow Jones)--Ernesto Bertarelli, chief executive of Serono SA (SRA), said it is misleading to compare its multiple sclerosis drug, Rebif, with fellow MS drug Tysabri.
Tysabri, which is developed by Biogen Idec (BIIB) and Elan Corp. (ELN), was approved by the Food and Drug Administration late Tuesday.
In a CNBC interview Wednesday, Bertarelli said there is no data that indicates Tysabri is any more effective that Rebif. He added that he expects Rebif to remain a market leader in the U.S. despite the entrance of Tysabri.
While a new MS alternative is great, Bertarelli said, Rebif has had a long history of proven safety and efficacy; however, no long-term studies of Tysabri have been done, he said.
"Bertarelli said there is no data that indicates Tysabri is any more effective that Rebif."
DUH! How about Rebif vs placebo compared to Tysabri vs placebo? Tysabri relaps decrease 66% vs Rebif relaps decrease of 33%. Sounds twice as good to me, not counting the side effects, on which the margin goes to Tysabri by a HUGE margin.